LTS strengthens its presence in China

On October 19, 2026, LTS celebrated the registration of 洛恒适医药咨询（上海）有限公司 LTS Lohmann Therapy Systems (China) Co., Ltd., with a ribbon-cutting ceremony.
The registration of the new entity marks the next step in LTS’s long-standing engagement in China and the broader Asian market. It builds on the company’s existing presence in China and further strengthens LTS’s position in the region.
“Establishing our own entity in China is a clear expression of our long-term commitment to this market,” says Detlev Radloff, President EMEA/A at LTS. “We want to continue developing our business here for the long term and further strengthen the trusted relationships we have built with our customers and partners.”
The Chinese company name 洛恒适 (Luò Héng Shì) also reflects this ambition. 洛 (Luò) represents the “L” and echoes the “Loh” sound in Lohmann; 恒 (Héng) conveys permanence and continuity, connecting LTS’s sustained drug delivery expertise with its commitment to long-term customer partnerships; and 适 (Shì) conveys comfort, reflecting LTS’s focus on drug delivery solutions designed with the patient experience in mind.
The opening was marked by a ribbon-cutting ceremony attended by Dr. Detlev Radloff, President EMEA/A, and Dr. Olaf Schrake, VP Business Development & Sales EMEA/A, and Geng Gao, General Manager of LTS Lohmann Therapy Systems (China) Co., Ltd.. LTS had also invited customers and partners, including representatives from AHK, Rödl and Osbon Clark, to attend the celebration.
With the establishment of its own legal entity in China, LTS is reinforcing its long-term commitment to the market and to building lasting partnerships with customers in the region.